US2493202A - Process of making a fluid oil-beeswax vehicle for the parenteral administration of drugs - Google Patents

Process of making a fluid oil-beeswax vehicle for the parenteral administration of drugs Download PDF

Info

Publication number
US2493202A
US2493202A US675312A US67531246A US2493202A US 2493202 A US2493202 A US 2493202A US 675312 A US675312 A US 675312A US 67531246 A US67531246 A US 67531246A US 2493202 A US2493202 A US 2493202A
Authority
US
United States
Prior art keywords
beeswax
vehicle
mixture
peanut oil
drugs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US675312A
Inventor
Thomas J Macek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Priority to US675312A priority Critical patent/US2493202A/en
Application granted granted Critical
Publication of US2493202A publication Critical patent/US2493202A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof

Definitions

  • This invention relates to the preparation of a new pharmaceutical vehicle. More particularly, it is concerned with the parenteral admin; istration of certain pharmaceutical preparations, which preparations include in addition to the therapeutic substance, a mixture of materials which prolongs the duration of an efiective level of the therapeutic compound in theblood.
  • a pharmaceutical vehicle which being fluid and. homogeneousacan be easily administered parenterally without. resorting to heating the vehicle and the hypodermic needle.
  • the process in accordance with the present invention comprises heating a mixture of beeswax and peanut oil for from I to 4 hours at a temperature between about,150-180,C. and rapidly cooling the resulting mixture thereby.
  • an improved pharmaceutical vehicle said vehicle being anhydrous, of fine particle size and gelatinous at room temperature-
  • Pharmaceutical vehicles prepared in accordance with my invention are useful as carriers for therapeutic substances such as penicillin, streptomycin and hormones.
  • an improved pharmaceutical vehicle is prepared by heating a mixture of beeswax and peanut oil in the ratio of 4.8 gms. of beeswax to cc. of the mixture at a temperature from about to C. for from 1 to 4 hours.
  • This mixture is rapidly cooled to room temperature with constant agitation.
  • the cooled suspension is fluid, homogeneous in nature, of a fine particle size, free of aggregates, large particles and coarse crystals and has a characteristic gelatinous structure which suspensions made by the usual means do not possess. It is therefore superior 3 to these suspensions. It is likely that during the heating process certain fractions of beeswax are extracted by the hot peanut oil and on cooling do not crystallize with the unextracted wax but impart a gelatinous character to the suspension.
  • Example 1 4.8 gm. of bleached beeswax are added to enough peanut oil to make 100 cc. and the mixture is warmed to about 70 C. When the beeswax has liquified, the mixture is stirred. The mixture contained in an Erlenmeyer flask is then heated at 165 C. for two hours. The flask is removed from the oven and the mixture is rapidly cooled and agitated by rotating the flask in a bath of water and ice. When cooled to room temperature, this mixture is a homogeneous, fluid, gelatinous suspension of beeswax in peanut oil and is free of aggregates, large particles and coarse crystals.
  • Example 2 of this vehicle is then triturated under sterile conditions with the required weight of sterile calcium penicillin, previously ground to pass through a 200 mesh sieve.
  • the suspension of calcium penicillin in the oil and wax vehicle is then subdivided into sterilized ampul vials and stoppered. Because the beeswax-peanut oil vehicle was heated to a high temperature it is anhydrous and is more suitable for the preparation of stable penicillin suspensions.
  • Example 3 A mixture consisting of 4.8%, weight to volume, of bleached beeswax in refined peanut oil is melted by heating to C. While liquid it is filtered free of fibers, etc. through a warmed, coarse, sintered-glass filter. The clear filtrate is then heated for 2 hours at C. The mixture is rapidly cooled and agitated by rotating the container in a bath of water and ice. The cooled vehicle is a sterilized, fluid, homogeneous, gelatinous suspension of finely-divided particles of beeswax in peanut oil. The required quantity of this vehicle is then triturated under sterile conditions with the required Weight of sterile streptomycin hydrochloride, previously ground to pass through a 200 mesh sieve. The suspension of streptomycin hydrochloride in the oil and wax vehicle is then subdivided into sterilized ampul vials and stoppered.
  • the process for producing an improved pharmaceutical vehicle for parenteral administration which comprises heating a mixture of 4.8 weight to volume of beeswax in peanut oil for from 1 to 4 hours at a temperature between 150 and C. and rapidly cooling the mixture with constant agitation thereby forming a vehicle consisting of a homogeneous suspension of finely divided particles of beeswax in peanut oil, said vehicle being fluid at room temperature.

Description

Patented Jan. 3, 1950 UNITED STATES PATENT OFFICE V 2 ,493,2c2' v p u I rnoonss :oE---MAKiNo 1r iLUI-n oiL-BEns- WAX VEHIGLE1FOR THE-:PARENTERAL VADMINISTRATION F DRUGS Thomas .I. Macek, irvington; N. a ssig'norto Merck &-Co., Inc., Rahway, N. J., a corporation of New Jersey No Drawing Application June 7, 1946, Serial No. 675,312
1 Claim. (01. iar-'82) This invention relates to the preparation of a new pharmaceutical vehicle. More particularly, it is concerned with the parenteral admin; istration of certain pharmaceutical preparations, which preparations include in addition to the therapeutic substance, a mixture of materials which prolongs the duration of an efiective level of the therapeutic compound in theblood.
The primary method for administering many therapeutic, substances, such as penicillin,strep tomycin. and many of the hormonesa has been by parenteral injections. For this purposefaqueous, saline or glucose solutions of the therapeutic compound have been injected. Because of, the rapid rate of absorption of the therapeutic compound into the blood stream and the rapid rate of excretion from the body through the urine, it has frequently been necessary to repeat the injections at various intervals to maintain therapeutically-effective blood concentrations for sufficiently long periods of time I u u w I Attempts were therefore made to provide a vehicle for administration along with therapeutic substances which would decrease the rate of absorption of the therapeutic substance thus prolonging the duration of an effective level inthe blood and which would be of gninimum inconvenience to the patient. It has been-recently reported that a beeswax-peanut oil vehicle prolonged the activity of penicillin in the blood when parenterally administered.
These vehicles have the serious disadvantage of solidifying at normal injection temperatures. In order to obtain a fluid suspension, it is necessary to warm the mixture to approximately 70 C. or to break up the latticework of wax crystals by stirring the mixture mechanically or shaking vigorously. Even after shaking, numerous masses of aggregates, large particles and coarse crystals are present which render such a suspension unsuitable for use as a vehicle for many pharma ceutical preparations and difiicult to handle through a hypodermic needle. Such suspensions are not gelatinous in structure and the Wax particles settle out of the oil suspension on standing. A beeswax-peanut oil mixture containing penicillin must be heated to about 70 C. until it becomes fluid prior to injection. It is also necessary to use a preheated hypodermic needle and syringe in administering the preparation. During this heating thepenicillin tends to settle from the Warm beeswax-peanut oil mixture and, upon cooling, a. non-homogeneous preparation often results. Repeated heating and cooling also tends to affect the stability of the penicillin in such a preparation. 7
It is the primary object of this invention to provide a suspension of beeswax and peanut oil Whichis homogeneous and fluid at room tom,- perature, of a uniform, finely-divided particle size and which has a characteristic gelatinous structure from which thewax particles do not rapidly separate onstanding. i I .It is a further object of this invention to proyide a pharmaceutical vehicle which being fluid and. homogeneousacan be easily administered parenterally without. resorting to heating the vehicle and the hypodermic needle.
It ,is ,a still further object of my invention to provide suspensions of beeswax. and peanut oil havingthese characteristics without mlllingor technical processing requiring special equipment. Regarded incertain of its broader aspects the process in accordance with the present invention comprises heating a mixture of beeswax and peanut oil for from I to 4 hours at a temperature between about,150-180,C. and rapidly cooling the resulting mixture thereby. forming an improved pharmaceutical vehicle, said vehicle being anhydrous, of fine particle size and gelatinous at room temperature- Pharmaceutical vehicles prepared in accordance with my invention are useful as carriers for therapeutic substances such as penicillin, streptomycin and hormones.
In accordance with a preferred embodiment of my invention an improved pharmaceutical vehicle is prepared by heating a mixture of beeswax and peanut oil in the ratio of 4.8 gms. of beeswax to cc. of the mixture at a temperature from about to C. for from 1 to 4 hours. This mixture is rapidly cooled to room temperature with constant agitation. During the heating process some change occurs through which the physical characteristics of the suspension are altered. The cooled suspension is fluid, homogeneous in nature, of a fine particle size, free of aggregates, large particles and coarse crystals and has a characteristic gelatinous structure which suspensions made by the usual means do not possess. It is therefore superior 3 to these suspensions. It is likely that during the heating process certain fractions of beeswax are extracted by the hot peanut oil and on cooling do not crystallize with the unextracted wax but impart a gelatinous character to the suspension.
Although I have obtained best results with a mixture of beeswax and peanut oil in the ratio of 4.8 gms. of beeswax to 100 cc. of the mixture this ratio can be varied to about 5 gms. of beeswax in 100 cc. of the mixture.
When suspensions of penicillin in a beeswaxpeanut oil vehicle prepared in accordance with my invention is injected into humans, the beeswax-peanut oil vehicle delays penicillin absorption and maintains a level in the blood for six to seven hours. The patient suffers no local pain or irritation in the region where the beeswaxpeanut oil mixture has been injected and. in certain treatments only one injection is necessary.
The following examples are given by way of illustration.
Example 1 4.8 gm. of bleached beeswax are added to enough peanut oil to make 100 cc. and the mixture is warmed to about 70 C. When the beeswax has liquified, the mixture is stirred. The mixture contained in an Erlenmeyer flask is then heated at 165 C. for two hours. The flask is removed from the oven and the mixture is rapidly cooled and agitated by rotating the flask in a bath of water and ice. When cooled to room temperature, this mixture is a homogeneous, fluid, gelatinous suspension of beeswax in peanut oil and is free of aggregates, large particles and coarse crystals.
Example 2 of this vehicle is then triturated under sterile conditions with the required weight of sterile calcium penicillin, previously ground to pass through a 200 mesh sieve. The suspension of calcium penicillin in the oil and wax vehicle is then subdivided into sterilized ampul vials and stoppered. Because the beeswax-peanut oil vehicle was heated to a high temperature it is anhydrous and is more suitable for the preparation of stable penicillin suspensions.
Example 3 A mixture consisting of 4.8%, weight to volume, of bleached beeswax in refined peanut oil is melted by heating to C. While liquid it is filtered free of fibers, etc. through a warmed, coarse, sintered-glass filter. The clear filtrate is then heated for 2 hours at C. The mixture is rapidly cooled and agitated by rotating the container in a bath of water and ice. The cooled vehicle is a sterilized, fluid, homogeneous, gelatinous suspension of finely-divided particles of beeswax in peanut oil. The required quantity of this vehicle is then triturated under sterile conditions with the required Weight of sterile streptomycin hydrochloride, previously ground to pass through a 200 mesh sieve. The suspension of streptomycin hydrochloride in the oil and wax vehicle is then subdivided into sterilized ampul vials and stoppered.
Various changes and modifications may be made in my process, certain preferred embodiments of which are described herein, which changes and modifications would, nevertheless, be within the scope of my invention. It is my intention that such changes and modifications, to the extent that they are within the scope of the appended claim, shall be considered as part of my invention.
I claim:
The process for producing an improved pharmaceutical vehicle for parenteral administration which comprises heating a mixture of 4.8 weight to volume of beeswax in peanut oil for from 1 to 4 hours at a temperature between 150 and C. and rapidly cooling the mixture with constant agitation thereby forming a vehicle consisting of a homogeneous suspension of finely divided particles of beeswax in peanut oil, said vehicle being fluid at room temperature.
THOMAS J. MACEK.
REFERENCES CITED The following references are of record in the file of this patent:
Penicillin, Its Practical Application, by
. Fleming (July 1946), page 52.
US675312A 1946-06-07 1946-06-07 Process of making a fluid oil-beeswax vehicle for the parenteral administration of drugs Expired - Lifetime US2493202A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US675312A US2493202A (en) 1946-06-07 1946-06-07 Process of making a fluid oil-beeswax vehicle for the parenteral administration of drugs

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US675312A US2493202A (en) 1946-06-07 1946-06-07 Process of making a fluid oil-beeswax vehicle for the parenteral administration of drugs

Publications (1)

Publication Number Publication Date
US2493202A true US2493202A (en) 1950-01-03

Family

ID=24709927

Family Applications (1)

Application Number Title Priority Date Filing Date
US675312A Expired - Lifetime US2493202A (en) 1946-06-07 1946-06-07 Process of making a fluid oil-beeswax vehicle for the parenteral administration of drugs

Country Status (1)

Country Link
US (1) US2493202A (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2746904A (en) * 1951-09-01 1956-05-22 Upjohn Co 17-hydroxycorticosterone, 21-beta-cyclopentyl propionate and compositions thereof
US2746978A (en) * 1951-09-01 1956-05-22 Upjohn Co Cortisone, 21-beta-cyclopentyl-propionate
US4310516A (en) * 1980-02-01 1982-01-12 Block Drug Company Inc. Cosmetic and pharmaceutical vehicle thickened with solid emulsifier
EP0211691A2 (en) * 1985-08-23 1987-02-25 Eli Lilly And Company Injectable sustained release formulation
US4775659A (en) * 1985-08-19 1988-10-04 Eli Lilly And Company Injectable semi-solid formulations
US4977140A (en) * 1985-08-23 1990-12-11 Eli Lilly And Company Injectable sustained release formulation
US5411951A (en) * 1984-10-04 1995-05-02 Monsanto Company Prolonged release of biologically active somatotropin
US5474980A (en) * 1984-10-04 1995-12-12 Monsanto Company Prolonged release of biologically active somatotropins

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2746904A (en) * 1951-09-01 1956-05-22 Upjohn Co 17-hydroxycorticosterone, 21-beta-cyclopentyl propionate and compositions thereof
US2746978A (en) * 1951-09-01 1956-05-22 Upjohn Co Cortisone, 21-beta-cyclopentyl-propionate
US4310516A (en) * 1980-02-01 1982-01-12 Block Drug Company Inc. Cosmetic and pharmaceutical vehicle thickened with solid emulsifier
US5411951A (en) * 1984-10-04 1995-05-02 Monsanto Company Prolonged release of biologically active somatotropin
US5474980A (en) * 1984-10-04 1995-12-12 Monsanto Company Prolonged release of biologically active somatotropins
US5595971A (en) * 1984-10-04 1997-01-21 Monsanto Company Prolonged release of biologically active polypeptides
US4775659A (en) * 1985-08-19 1988-10-04 Eli Lilly And Company Injectable semi-solid formulations
AU596806B2 (en) * 1985-08-19 1990-05-17 Eli Lilly And Company Injectable semi-solid formulations
EP0211691A2 (en) * 1985-08-23 1987-02-25 Eli Lilly And Company Injectable sustained release formulation
EP0211691A3 (en) * 1985-08-23 1987-06-03 Eli Lilly And Company Injectable sustained release formulation
US4977140A (en) * 1985-08-23 1990-12-11 Eli Lilly And Company Injectable sustained release formulation

Similar Documents

Publication Publication Date Title
US3089815A (en) Injectable pharmaceutical preparation, and a method of making same
DE69217056T4 (en) Taxane derivatives containing drugs
US2493202A (en) Process of making a fluid oil-beeswax vehicle for the parenteral administration of drugs
CH638806A5 (en) METHOD FOR PRODUCING NEW 4-AMINO-4-ARYLCYCLOHEXANONE KETALS.
KR102507678B1 (en) Aripiprazole sustained-release microspheres and preparation method thereof
JPH05501268A (en) Injectable sustained release formulation
KR880002087B1 (en) Process for preparing salts of antimicrobial naphthyridine and quinoline compounds
US2661315A (en) Prolonged-effectiveness injectable therapeutic preparation
US2518510A (en) Stable injectable oil-pectin therapeutic compositions
US2530480A (en) Therapeutic preparations for intramuscular and subcutaneous injection and methods of making the same
US2487975A (en) Therapeutic preparations for intramuscular or subcutaneous injection and methods of making the same
US2650217A (en) Production of quinine-penicillin
JPS61257924A (en) Medicinal composition for treating cerebral marasum sympton and psychotic decline
JPH0512328B2 (en)
DENIKER PSYCHOPHYSIOLOGIC ASPECTS OF THE NEW CHEMOTHERA-PEUTIC DRUGS IN PSYCHIATRY: Some Practical Features of “Neuroleptics” in Order to Screen New Drugs
US2656299A (en) Penicillin compositions
DE19912436A1 (en) Ibuprofen solution
DE1806926A1 (en) Lithium salt of hydroquinone sulfonic acid
DE2951142A1 (en) Stable suppository - contg. indolyl:acetic acid antiinflammatory, phosphatidyl choline and tri:glyceride base
US2476351A (en) Injectable penicillin compositions
US2719103A (en) D-tubo-curarine chloride in suspension of water-insoluble soap in injectable oil
Shouse et al. I. EFFECTS OF THE INTRAVENOUS INJECTION OF COLLOIDAL SILVER UPON THE HEMATOPOIETIC SYSTEM IN DOGS
CN101416946A (en) Adopt vibrating diaphragm technology to prepare biodegradable implanting controlled release microsphere and method for making thereof
US2694665A (en) Procaine-penicillin g composition
US2537988A (en) Sympatholytic compositions